Scarica l'app Stockscreener
26.71
0.45%
0.12
Dopo l'orario di chiusura:
26.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$26.59
Aprire:
$26.68
Volume 24 ore:
1.10M
Relative Volume:
0.61
Capitalizzazione di mercato:
$3.27B
Reddito:
$317.93M
Utile/perdita netta:
$-44.32M
Rapporto P/E:
-75.35
EPS:
-0.3545
Flusso di cassa netto:
$-48.24M
1 W Prestazione:
+2.45%
1M Prestazione:
-0.26%
6M Prestazione:
+81.21%
1 anno Prestazione:
+102.20%
Intervallo 1D:
$25.89
$26.76
Intervallo di 1 settimana:
$25.84
$27.62
Portata 52W:
$11.55
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.71 | 3.26B | 317.93M | -44.32M | -48.24M | -0.3545 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis at Guggenheim Summit: Strategic Growth and Market Expansion By Investing.com - Investing.com Canada
Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal - MarketBeat
Have Insiders Sold Arcutis Biotherapeutics Shares Recently? - simplywall.st
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup - ChartMill
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A Promising 18.12% Upside Potential for Investors - DirectorsTalk Interviews
Implied Volatility Surging for Arcutis Biotherapeutics Stock Options - Yahoo Finance
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit - AOL.com
Can Arcutis Biotherapeutics Inc sustain earnings growthWeekly Investment Summary & Consistent Profit Alerts - baoquankhu1.vn
Pullback Watch: What is the PEG ratio of Arcutis Biotherapeutics Inc2025 Earnings Surprises & Weekly Top Stock Performers List - baoquankhu1.vn
Trading the Move, Not the Narrative: (ARQT) Edition - Stock Traders Daily
Positive Infant Trial Data For ZORYVE Might Change The Case For Investing In Arcutis Biotherapeutics (ARQT) - Yahoo Finance
Baron Health Care Fund is Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT) - Insider Monkey
Baron Health Care Fund: Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT) - Yahoo Finance UK
Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule - marketscreener.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Biotherapeutics CEO Watanabe sells $505,709 in ARQT stock By Investing.com - Investing.com Canada
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 40,638 Shares of Stock - MarketBeat
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus
Edwards Larry Todd sells Arcutis Biotherapeutics shares for $52,322 By Investing.com - Investing.com Canada
Arcutis Biotherapeutics EVP Burnett sells $346,453 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics EVP Burnett sells $346,453 in stock - Investing.com
Arcutis Biotherapeutics director Welgus sells $250k in shares By Investing.com - Investing.com Canada
Arcutis Biotherapeutics CFO Vairavan sells $33657 in stock By Investing.com - Investing.com Canada
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Sells $33,660.00 in Stock - MarketBeat
Todd Watanabe Sells 19,833 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat
Larry Todd Edwards Sells 2,052 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 3,675 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics CFO Vairavan sells $33657 in stock - Investing.com
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Exploring a 24% Upside Potential in the Booming Biotech Sector - DirectorsTalk Interviews
Aug Sectors: Is Arcutis Biotherapeutics Inc stock good for income investorsJuly 2025 Weekly Recap & Verified Trade Idea Suggestions - baoquankhu1.vn
Arcutis reports positive results for eczema cream in infants By Investing.com - Investing.com Nigeria
Arcutis reports positive phase 2 data for roflumilast cream (Zoryve) in infants with atopic dermatitis - Contemporary Pediatrics
Arcutis Biotherapeutics (ARQT) Reports Positive Phase 2 Trial Re - GuruFocus
Arcutis reports positive results for eczema cream in infants - Investing.com
Arcutis Biotherapeutics Reports Positive Phase 2 Results for ZORYVE Cream 0.05% in Infants with Atopic Dermatitis - Quiver Quantitative
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis - The Manila Times
Infant eczema cream helped 58% of patients in 4-week Arcutis study - Stock Titan
Tejara Capital Ltd Sells 352,878 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Published on: 2026-01-30 11:27:41 - baoquankhu1.vn
AI Stocks: What are analysts price targets for Arcutis Biotherapeutics Inc2025 Major Catalysts & Risk Managed Trade Strategies - baoquankhu1.vn
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A Promising Biotech Play with 20.63% Potential Upside - DirectorsTalk Interviews
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa - Yahoo Finance
Growth Review: Can Arcutis Biotherapeutics Inc stock outperform in a bear marketWeekly Profit Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Arcutis terminates promotion agreement with Kowa for ZORYVE By Investing.com - Investing.com Nigeria
(ARQT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Swing Trade: Is Alaunos Therapeutics Inc a turnaround story2025 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Arcutis Biotherapeutics (ARQT) Sees Target Price Boost from Needham | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):